


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-1.53%
+3.96%
-2.47%
+6.79%
ALT
Altimmune
$3.62
Strengths

Earnings are forecast to grow
ALT Price Performance
$4.57 (-20.79%)
$5.28 (-31.44%)
$3.89 (-6.94%)
$5.57 (-35.01%)
Overall standing based on market and analyst consensus.
Hover over the category for more information
Earnings
Earnings
Below analyst estimate
Reported a strong earnings
Rating
Rating
Momentum
Momentum
Price value has negative momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
ALT Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
ALT Street Sentiment is unimpressive and have negative views on the near-term outlook
ALT has Fair risk level
Risk Indicators
Sentiments overview associated with events and the stock performance
Average key support and resistance price levels
Recent Upgrades and Downgrades
Nov 08, 2025
Reiterate
Outperform
Citizens
Oct 20, 2025
Reiterate
Buy
HC Wainwright & Co.
Oct 10, 2025
Reiterate
Buy
HC Wainwright & Co.
What is ALT current stock price?
What are ALT stock strengths?
What is ALT Risk Level?
What is ALT market cap and volume?
What is ALT current Stock IQ?
Should I buy ALT stock right now?
Is ALT a Strong Buy right now?
What does a 'Strong Buy' rating mean for ALT?
What does a 'Strong Sell' rating mean for ALT?
What factors influence ALT's Stock IQ?
Join our subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
ALT
Altimmune
Current Price
$3.62

ALT Price Performance
$4.57 (-20.79%)
$5.28 (-31.44%)
$3.89 (-6.94%)
$5.57 (-35.01%)
ALT Analysts Opinion
Overall standing per market and analyst expectations.
Hover over the category for more information
Earnings
Earnings
Below analyst estimate
Reported a strong earnings
Rating
Rating
Momentum
Momentum
Price value has negative momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
ALT Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
ALT Street Sentiment is unimpressive and have negative views on the near-term outlook
ALT has Fair risk level
Risk Indicators
Average key support and resistance price levels
Overall Wall Street Rating
ALT Stock IQ
Stock Insights
Strengths

Earnings are forecast to grow
ALT Latest Analysis
Altimmune Reports FY25 Financials: Why Is Big Pharma Staying Away.
Fri Mar 6, 2026
Altimmune Inc. (NASDAQ:ALT) Q4 2025 Earnings Call Transcript. Altimmune Inc. (NASDAQ:ALT) Q4 2025 Earnings Call Transcript March 5 2026 Altimmune Inc. misses on earnings expectations. Reported EPS is $-0.27191 EPS expectations were $-0.25. Operator: Good morning ladies and gentlemen and welcome to the Altimmune Inc. year-end 2025 financial results conference call. After the speakers’. presentation there will be a question-and-answer session. You will [….]
Fri Mar 6, 2026
Altimmune GAAP EPS of -$0.27 misses by $0.03 revenue of $0.03M beats by $0.03M.
Thu Mar 5, 2026
What to Expect from Altimmunes Earnings.
Altimmune (NASDAQ:ALT) is preparing to release its quarterly earnings on Thursday 2026-03-05. Here'.s a brief overview of what investors should keep in mind before the announcement.
Analysts expect Altimmune to report an earnings per share (EPS) of $-0.25.
Altimmune s will hope to hear the company announce they'.ve not only beaten that estimate but also to prov
Wed Mar 4, 2026
Altimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5 2026. GAITHERSBURG Md. Feb. 26 2026 (GLOBE NEWSWIRE) -- Altimmune Inc. (Nasdaq: ALT) a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases today announced that it will report its fourth quarter 2025 financial results on Thursday March 5 2026.
Thu Feb 26, 2026
FIND US ON
Unlock the knowledge that 5,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained.
The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.